Endometrial cancer with implantation metastasis to vagina: a case report

Authors present a case of vaginal implantation metastasis following a diagnosis of endometrial cancer. A 58-year-old lady presented with postmenopausal bleeding and was later diagnosed to have endometrial cancer. She underwent an extra-fascial hysterectomy and bilateral salpingo-oophrorectomy with pelvic lymphadenectomy for Stage 3A endometrioid adenocarcinoma of the endometrium. The lymph nodes and cervix were free from the disease and no lymphovascular invasion was seen on the pathological specimen. She defaulted adjuvant radiotherapy and was lost to follow up. Six months later she had a tumour recurrence at the vaginal introitus just below the urethral orifice and awal from the vaginal vault with similar histopathological findings as previous cancer. This case highlights the rare occurrence of implantation metastasis of endometrial cancer.

Download Full-text

Treatment of endometrial cancer at the Joliot Curie Institute in Dakar: about 30 cases

African Journal of Oncology ◽

10.54266/ajo.1.1.28.28 ◽

2021 ◽

Vol 1 (1) ◽

pp. 28-30

Author(s):

Jaafar Thiam ◽

E Kahatwa ◽

Sidy Ka ◽

Mamadou Moustapha Dieng ◽

Doudou Diouf ◽

...

Keyword(s):

Radiation Therapy ◽

Endometrial Cancer ◽

Stage Iv ◽

Pelvic Lymphadenectomy ◽

Common Type ◽

Endometrioid Adenocarcinoma ◽

External Radiotherapy ◽

Radiation Cystitis ◽

Effective Treatment Modality

AIM: To study the therapeutic aspects of endometrial cancer at the Joliot Curie Institute in Dakar. MATERIALS AND METHODS: This is a retrospective study conducted at the Joliot Curie Institute in Dakar including all cases of endometrial cancer confirmed by histology between January 2012 and December 2016. RESULTS: There were 30 cases of endometrial cancer over a period of five years. Endometrioid adenocarcinoma was the most common type of histology and was found in 25 patients, or 84% of cases. The patients were classified as stages I and II of FIGO in 43% of cases, stage III in 24% of cases and stage IV in 33% of cases. Colpo-hysterectomy with pelvic lymphadenectomy (CHL) was the main surgical procedure performed. External radiotherapy was performed in three patients or 10%. A case of radiation cystitis and radiodermatitis were recorded as a radiotherapy complication. No patient received brachytherapy. Chemotherapy was performed in 17 patients, ie 56.6%. She was adjuvant in 10 patients, or 34% of cases. Pelvic recurrences were noted in three patients who underwent 10% surgery. After 13 months of follow-up, survival was 50%. CONCLUSION: The most effective treatment modality for endometrial cancer at the Joliot Curie Institute was surgery followed by chemotherapy and Radiation therapy.

Download Full-text

Endometrial Cancer with Sarcoidosis in Regional Lymph Nodes: A Case Report

Case Reports in Oncology ◽

10.1159/000440800 ◽

2015 ◽

Vol 8 (3) ◽

pp. 409-415 ◽

Cited By ~ 2

Author(s):

Satoshi Tamauchi ◽

Yuji Shimomura ◽

Hiromi Hayakawa

Keyword(s):

Endometrial Cancer ◽

Lymph Node ◽

Lymph Nodes ◽

Pelvic Lymphadenectomy ◽

Preoperative Imaging ◽

Endometrioid Adenocarcinoma ◽

Regional Lymph Nodes ◽

Lymph Node Swelling ◽

Histological Confirmation ◽

Noncaseating Granulomas

Sarcoidosis is a chronic, multisystemic disease commonly affecting the lungs and lymphatic system and is characterized by the formation of noncaseating granulomas. Although several reports are available on cases developing both sarcoidosis and cancer metachronously, cases of simultaneous diagnosis of these diseases have rarely been reported. A 67-year-old woman diagnosed with endometrial cancer had developed systemic lymph node swelling, including bilateral hilar, paraaortic, and a few pelvic lymph nodes, as observed on preoperative imaging. During surgery, frozen sections of a paraaortic lymph node were examined, revealing noncaseating granulomas compatible with sarcoidosis. Next, modified radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy were performed. Postoperative pathological analysis revealed endometrioid adenocarcinoma of the uterus, and no metastasis but noncaseating granulomas were detected in the resected lymph nodes. Postoperatively, we identified cutaneous sarcoidosis and uveitis in the presence of a tuberculin-negative test. On the basis of these findings, we diagnosed the patients with endometrial cancer complicated by sarcoidosis. She underwent adjuvant chemotherapy, and at the 1-year follow-up, the lymph node swelling due to sarcoidosis was stable, and no recurrence of the cancer was observed. This turned out to be a case of early endometrial cancer mimicking advanced cancer by sarcoidosis. Histological confirmation and additional examination for sarcoidosis are necessary in cancer patients suspected of sarcoidosis.

Download Full-text

External Beam, Brachytherapy, or Chemotherapy? Defining Adjuvant Therapy for Early-Stage and High- and High–Intermediate-Risk Endometrial Cancer

Journal of Clinical Oncology ◽

10.1200/jco.19.00362 ◽

2019 ◽

Vol 37 (21) ◽

pp. 1778-1784 ◽

Cited By ~ 3

Author(s):

Joanne Wei-un Jang ◽

Larissa Janeen Lee

Keyword(s):

Endometrial Cancer ◽

Early Stage ◽

Relevant Literature ◽

Myometrial Invasion ◽

Laparoscopic Hysterectomy ◽

Figo Stage ◽

Pelvic Lymphadenectomy ◽

Endometrioid Adenocarcinoma ◽

Pelvic Magnetic Resonance Imaging ◽

Gynecology And Obstetrics

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 54-year-old postmenopausal female with a history of stroke and carotid endarterectomy presented with 3 weeks of vaginal bleeding with passage of clots. Gynecologic exam revealed a 3-cm barrel-shaped cervix with friability at the os and no appreciable parametrial involvement. Cervical biopsy showed high-grade endometrioid adenocarcinoma. Pelvic magnetic resonance imaging demonstrated a 9.9-cm × 4.5-cm × 6.2-cm mass extending from the uterus to the cervix with greater than 50% myometrial invasion (MMI; Fig 1 ). Total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy revealed International Federation of Gynecology and Obstetrics (FIGO) stage II endometrial cancer: a 12-cm grade 3 endometrioid adenocarcinoma with 80% MMI and lymphovascular invasion (LVI) involving the outer half of the cervical stroma ( Fig 1 ), and without pelvic lymph node involvement.

Download Full-text

Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report

Tumors of female reproductive system ◽

10.17650/1994-4098-2019-15-1-73-77 ◽

2019 ◽

Vol 15 (1) ◽

pp. 73-77

Author(s):

T. T. Andabekov ◽

M. K. Rodina ◽

G. A. Raskin ◽

K. G. Cham ◽

I. O. Rutkin

Keyword(s):

Endometrial Cancer ◽

Partial Response ◽

Mismatch Repair ◽

Malignant Tumors ◽

Short Review ◽

Endometrioid Adenocarcinoma ◽

Mismatch Repair Deficiency ◽

Repair Deficiency ◽

Anticancer Treatment

High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events.

Download Full-text

Clinicopathologic characteristics of endometrial cancer in Lynch syndrome.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.5098 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 5098-5098

Author(s):

Fabrice Lecuru ◽

Julie Bouquier ◽

marie-Aude le Frere-Belda ◽

Cherazade Bensaid ◽

Claude Nos ◽

...

Keyword(s):

Endometrial Cancer ◽

Lynch Syndrome ◽

Age At Onset ◽

Lower Uterine Segment ◽

High Rate ◽

Serous Carcinoma ◽

Endometrioid Adenocarcinoma ◽

Clinicopathologic Characteristics ◽

Stage Ib

5098 Background: Poor data exist on clinico-pathological description of endometrial cancer (EC) in Lynch syndrome (LS) compared with sporadic ones. To evaluate the clinico-pathological findings of Lynch-related EC to establish histological criteria to discriminate familial and sporadic EC and to decide the optimal management of patients. Methods: Retrospective study of prospective cohort of patients with LS in our institution from 1999 to 2011. We identified and described all cases of endometrial cancers. Management and follow-up were detailed. Results: Of a cohort of 126 patients with LS, 10 women developed endometrial carcinoma. The median age at diagnosis was 51 years (41-58). Five patients had an identified mutation (2 hMLH1, 2 hMSH2 and 1 hMSH6). In 9 cases, EC was the first Lynch-related tumor to occur. No patient developed ovarian cancer. All, except 2 patients (1 serous carcinoma and 1 clear cell carcinoma), had endometrioid adenocarcinoma (80%). Tumor grade was grade 1 in 3 patients, grade 2 in 5 and grade 3 in 2 patients. Forty per cent of patients had lymphovascular space involvement (LVSI). The FIGO stages were as follows: stage IA (n=7), stage IB (n=2) and stage IIIC (n=1). Four in ten patients had tumor located in the lower uterine segment. With a median follow-up of 14 months (range 9 – 40 months), recurrence occurred in one patient with a stage IB grade 2 endometrioid adenocarcinoma with LVSI. Conclusions: EC in LS is characterized by early age at onset, localization in lower uterine segment, and high rate of LVSI. Other data on histology and survival do not differ from sporadic cancers. These results suggest that we can consider conservative treatment in patients with good prognosis tumors. Further studies are required.

Download Full-text